The CHMP positive opinion is a transformative regulatory milestone that significantly increases the probability of European approval and Menarini-led launch in late 2026. Key upcoming catalysts: EC final decision, PREVAIL interim analysis (Q1 2027), RUBENS topline (YE 2026), and a potential Alzheimer's trial start. Monitor the Investor Day webcast for strategic details.
Price Chart
Executive Summary
NewAmsterdam Pharma reported Q2 2026 results alongside the announcement that the CHMP has adopted a positive opinion recommending marketing authorization for obicetrapib (Ubeslo) and obicetrapib/ezetimibe FDC (Evlarco) in Europe — the most significant catalyst to date. Net loss widened to $64.1M from $17.4M a year ago on higher R&D costs and non-recurring Menarini milestone revenue in the prior-year period, but cash remains ample at $678.3M.
Key Facts
- CHMP positive opinion for obicetrapib 10 mg and FDC with ezetimibe; European Commission decision expected in 2H26
- Cash, cash equivalents and marketable securities of $678.3M at June 30, 2026
- Net loss of $64.1M in Q2 2026 vs $17.4M in Q2 2025
- Revenue of $3.7M vs $19.1M prior year (prior-year included $16.1M development cost contribution from Menarini)
- PREVAIL interim analysis planned for Q4 2026 with result in Q1 2027
- RUBENS Phase 3 topline data expected by year-end 2026
- Investor Day held on August 5, 2026
Financial Impact
Positive CHMP opinion substantially de-risks European approval; potential peak sales in Europe for obicetrapib are not disclosed but the addressable market includes >30M under-treated patients in the U.S. alone. Near-term financials are secondary to regulatory and clinical milestones.
Risk Factors
- European Commission may not follow the CHMP recommendation, though this is rare
- PREVAIL CVOT failure or underwhelming interim results could significantly impair the asset's value
- Commercial execution risk if approved, despite Menarini partnership
- Cash burn of ~$70M per six months provides runway but could necessitate future financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-333827 |
| Document: nams-20260805.htm | 0001193125-26-333827 |
| Document: 0001193125-26-333827-index-headers.html | 0001193125-26-333827 |
| Document: 0001193125-26-333827-index.html | 0001193125-26-333827 |
| Document: 0001193125-26-333827.txt | 0001193125-26-333827 |
| 8-K Data (Synthetic) | 0001193125-26-333827 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Buy | $21.16 $23.32 | ▲ +10.21% | ▲ +8.08% | $22.97 (+8.55%) |
Aug 5, 2026 8w ago | 8-K | $27.42 $27.83 | ▲ +1.50% | ▲ +1.14% | $22.97 (−16.23%) |
Jul 24, 2026 10w ago | 8-K | $29.64 $28.46 | ▼ −3.98% | ▼ −4.35% | $22.97 (−22.50%) |
Apr 8, 2026 25w ago | Press Release | $34.01 $34.01 | · 0.00% | ▼ −3.52% | $22.97 (−32.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access